GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: Emflaza® | MDL 458
                                 deflazacort is an approved drug (UK (1994), FDA (2017)) Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Deflazacort is a prednisolone derivative glucocorticoid that is used as an anti-inflammatory and immunosuppressant. It is a prodrug that is metabolised to the active form, 21-desacetyl deflazacort (PubChem CID 97547130) [3].
                                    
                                   View more information in the IUPHAR Pharmacology Education Project: deflazacort | 
 | |||||||||||||||||||||||||||||||||||
| References | 
| 1. Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley 3rd RT, King W, Kissel JT, Cwik V et al.. (2016) Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology, 87 (20): 2123-2131. [PMID:27566742] | 
| 2. Luzzani F, Glässer A. (1981) Differential binding in vitro to glucocorticoid receptors of deflazacort and prednisolone. Eur J Pharmacol, 76 (4): 427-30. [PMID:7327211] | 
| 3. Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. (1995) Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res, 12 (7): 1096-100. [PMID:7494809] |